Navigation Links
PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
Date:10/5/2009

ANNAPOLIS, Md., Oct. 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that company President and Chief Executive Officer, David P. Wright and Dr. Valerie Riddle, Vice President and Medical Director, were featured in the Homeland Security Television Channel (HSTV) 30-minute documentary training video entitled, "Deadly Pathogen: Exploring the Anthrax Threat," which was distributed to 65,000 members of the U.S. Department of Homeland Security.

The HSTV Deadly Pathogen documentary video provides an in-depth analysis of the biological agent, Bacillus Anthracis, the bacteria that causes anthrax, and details what this deadly pathogen does to the human body and why it remains such an imminent threat to the security of millions of people worldwide.

The training video was broadcast on the HSTV Threat Matrix Show that investigates current trends and issues in Homeland Security. The show takes an investigative approach to the policy and technology challenges and emerging threats facing the homeland security community.

"We are delighted to share our expertise with the U.S. Department of Homeland Security on anthrax weaponization, anthrax disease pathogenesis, and promising, second generation vaccine product candidates to address this biological threat," commented David P. Wright. "PharmAthene is developing a second generation recombinant protective antigen (rPA) anthrax vaccine called SparVax(TM) to protect civilians and the military and to advance our company goal of becoming the leading provider of best-in-class medical countermeasures for the biodefense industry."

The HSTV Deadly Pathogen: Exploring the Anthrax Threat 30-minute documentary video can be viewed on the link below.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
2. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
3. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
4. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
5. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
6. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
7. PharmAthene Reports First Quarter 2009 Financial and Operational Results
8. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
9. PharmAthene to Host First Quarter 2009 Conference Call and Webcast on Thursday, May 14, 2009
10. PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
11. PharmAthene Announces $5.5 Million Public Equity Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... 1 safety studies, and plans for Phase 2 studies ... to be presentedCINCINNATI, May 14 Ausio Pharmaceuticals, LLC, ... aging global population, will lead off the Bio(R) Business ... 9:00 AM in Atlanta, Georgia. Ausio has developed AUS-131, ...
... Phase 3 CAPACITY results poster presentation Sunday, May 17, 8:15 ... presentation, Tuesday, May 19, 3:35 p.m. PDT - - ... - BRISBANE, Calif., May 14 InterMune, Inc. (Nasdaq: ... presentation and two poster discussion presentations related to the company,s ...
... with substantially increased capacity, for continued ... announced today robust double digit growth in sales, improved ... quarter ended March 31, 2009. , In a news ... "Our 43% growth in the first half of 2009 ...
Cached Biology Technology:Ausio Pharmaceuticals to Present at Bio(R) 2009 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 2Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 3Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 4Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS 5Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 2Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 3Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09 4
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... MOUNTAIN VIEW, CA January 25, 2011 23andMe,s ... both phenotypic and genetic data from 500 individuals diagnosed ... way towards its goal of building a sarcoma research ... completed its Independent Sarcoma Scientific Advisory Committee with the ...
... lethal form of brain cancer and the disease that ... efforts, even when attacked simultaneously on several fronts. One ... flexibility, discovered researchers at the Salk Institute for Biological ... glioblastoma cells can shift gears and morph into blood ...
... Baltimore, Md. (January 24, 2011) A research effort designed ... a research hatchery could end up helping Chesapeake Bay watermen ... shell crabs perishing before reaching the market. The findings, published ... that the transmission of a crab-specific virus in diseased and ...
Cached Biology News:23andMe sarcoma research community reaches 500 and announces Sarcoma Scientific Advisory Committee 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 2Conversion of brain tumor cells into blood vessels thwarts treatment efforts 3Blue crab research may help Chesapeake Bay watermen improve soft shell harvest 2
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
...
Rabbit polyclonal to LCAT ( Abpromise for all tested applications). entrezGeneID: 3931 SwissProtID: P04180...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
Biology Products: